1. Home
  2. ELTX vs NEN Comparison

ELTX vs NEN Comparison

Compare ELTX & NEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$3.60

Market Cap

185.4M

Sector

Health Care

ML Signal

HOLD

Logo New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

NEN

New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

HOLD

Current Price

$57.98

Market Cap

209.2M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELTX
NEN
Founded
2011
1977
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Building operators
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
185.4M
209.2M
IPO Year
2014
1995

Fundamental Metrics

Financial Performance
Metric
ELTX
NEN
Price
$3.60
$57.98
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$18.00
N/A
AVG Volume (30 Days)
4.0M
1.2K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
2.71%
EPS Growth
39.29
N/A
EPS
N/A
N/A
Revenue
$2,301,000.00
$89,196,544.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$19.68
Revenue Growth
N/A
10.76
52 Week Low
$2.66
$55.61
52 Week High
$16.00
$74.00

Technical Indicators

Market Signals
Indicator
ELTX
NEN
Relative Strength Index (RSI) 37.20 46.26
Support Level $2.66 $56.83
Resistance Level $9.44 $60.90
Average True Range (ATR) 0.82 1.29
MACD -0.05 -0.13
Stochastic Oscillator 20.93 47.40

Price Performance

Historical Comparison
ELTX
NEN

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership

New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating, and selling real estate. The Partnership owns and operates various residential apartments, condominium units, and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent, and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.

Share on Social Networks: